Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

被引：0
|
作者：
Rummel, Mathias J.
Buske, Christian
Hertenstein, Bernd
Lerchenmueller, Christian
Koenigsmann, Michael
Lange, Elisabeth
Reeb, Manfred
Kaiser, Ulrich
Balser, Christina
Behringer, Dirk
Durig, Jan
Gaska, Tobias
Maschmeyer, Georg
Schliesser, Georg
Burchardt, Alexander Christoph
Barth, Juergen
Kauff, Frank
Hinke, Axel
Greil, Richard
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
483
引用
收藏
页数：3
相关论文
共 49 条
  • [41] R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
    Sancho, Juan-Manuel
    Fernandez-Alvarez, Ruben
    Gual-Capllonch, Francisco
    Gonzalez-Garcia, Esther
    Grande, Carlos
    Gutierrez, Norma
    Penarrubia, Maria-Jesus
    Batlle-Lopez, Ana
    Gonzalez-Barca, Eva
    Guinea, Jose-Maria
    Gimeno, Eva
    Penalver, Francisco-Javier
    Fuertes, Miguel
    Bastos, Mariana
    Hernandez-Rivas, Jose-angel
    Moraleda, Jose-Maria
    Garcia, Olga
    Sorigue, Marc
    Martin, Alejandro
    CANCER MEDICINE, 2021, 10 (04): : 1314 - 1326
  • [42] Interim Results From a Phase II Study Of Non-Anthracycline Combination Of Oxaliplatin-Gemcitabine Plus Rituximab (R-GemOx) As First-Line Treatment In Elderly Patients With Diffuse Large B-Cell Lymphoma
    Fan, Lei
    Wang, Li
    Xu, Ji
    Zhang, Run
    Yang, Yuqiong
    Huang, Dongping
    Shen, Yunfeng
    Zhou, Min
    Yu, Liang
    Zhang, Zhihong
    Xu, Wei
    Li, Jianyong
    BLOOD, 2013, 122 (21)
  • [43] A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization
    Lopez-Guillermo, Armando
    Canales, Miguel A.
    Dlouhy, Ivan
    Briones, Javier
    Caballero, Dolores
    Sancho, Juan Manuel, Sr.
    Vilchez, Santiago Mercadal
    Moraleda, Jose Maria
    Terol, Maria Jose
    Salar, Antonio
    Palomera, Luis
    Gardella, Santiago
    Jarque, Isidro
    Ferrer, Secundino
    Bargay, Joan
    Lopez, Andres
    Panizo, Carlos
    Muntanola, Anna
    Montalban, Carlos
    Conde, Eulogio
    Hernandez, Miguel
    Soler, Alfons
    Marin, Julian
    Marco, Jose Garcia
    Deben, Guillermo
    Tomas, Jose Francisco
    BLOOD, 2013, 122 (21)
  • [44] A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
    Lopez-Guillermo, Armando
    Canales, Miguel Angel
    Dlouhy, Ivan
    Mercadal, Santiago
    Briones, Javier
    Martin Garcia-Sancho, Alejandro
    Sancho, Juan Manuel
    Maria Moraleda, Jose
    Terol, Maria Jose
    Salar, Antonio
    Palomera, Luis
    Gardella, Santiago
    Jarque, Isidro
    Ferrer, Secundino
    Bargay, Joan
    Lopez, Andres
    Panizo, Carlos
    Muntanola, Anna
    Montalban, Carlos
    Conde, Eulogio
    Hernandez, Miguel T.
    Soler, Alfons
    Garcia Marco, Jose A.
    Deben, Guillermo
    Marin, Julian
    Tomas, Jose Francisco
    LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 93 - 100
  • [45] Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study
    Le Gouill, Steven
    Thieblemont, Catherine
    Oberic, Lucie
    Bouabdallah, Krimo
    Gyan, Emmanuel
    Damaj, Gandhi
    Ribrag, Vincent
    Bologna, Serge
    Gressin, Remy
    Casasnovas, Olivier
    Haioun, Corinne
    Solal-Celigny, Philippe
    Maisonneuve, Herve
    Van Den Neste, Eric
    Moreau, Anne
    Bene, Marie C.
    Salles, Gilles
    Tilly, Herve
    Lamy, Thierry
    Hermine, Olivier
    BLOOD, 2014, 124 (21)
  • [46] Rituximab Maintenance Versus Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a LYSA Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 17 - 18
  • [47] R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo
    Sancho, Juan-Manuel
    Gual, Francisco
    Fernandez-Alvarez, Ruben
    Gonzalez-Garcia, Esther
    Grande, Carlos
    Jimenez-Lopez, Carmen
    Gutierrez, Norma C.
    Penarrubia, Maria-Jose
    Batlle, Ana
    Gonzalez-Barca, Eva
    Guinea-de-Castro, Jose-Maria
    Gimeno, Eva
    Penalver, Francisco-Javier
    Fuertes, Miguel A.
    Gayoso, Jorge
    Hernandez-Rivas, Jose-Angel
    Moraleda, Jose-MariA
    Virgili, Lluis
    Martin, Alejandro
    BLOOD, 2016, 128 (22)
  • [48] High CR rate and prolonged EFS in aaIPI 2-3 diffuse large B-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen):: Results of a prospective phase II multicenter study sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
    Tarella, C
    Zanni, M
    Di Nicola, M
    Patti, C
    Castellino, C
    Pescarollo, A
    Zoli, V
    Caracciolo, D
    Ladetto, M
    Magni, M
    Devizzi, L
    Boccadoro, M
    Bregni, M
    Corradini, P
    Gallamini, A
    Majolino, I
    Mirto, S
    Gianni, AM
    BLOOD, 2005, 106 (11) : 585A - 585A
  • [49] A RANDOMIZED MULTICENTRE PHASE III STUDY FOR FIRST LINE TREATMENT OF YOUNG PATIENTS WITH HIGH RISK (AAIPI 2-3) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RITUXIMAB (R) PLUS DOSE-DENSE CHEMOTHERAPY CHOP14/MEGACHOP14 WITH OR WITHOUT INTENSIFIED HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). RESULTS OF DLCL04 TRIAL OF ITALIAN LYMPHOMA FOUNDATION (FIL)
    Vitolo, U.
    Chiappella, A.
    Brusamolino, E.
    Angelucci, E.
    Balzarotti, M.
    Carella, A. M.
    Ciccone, G.
    Gaidano, G.
    Merli, F.
    Pane, F.
    Pavone, V.
    Rossi, G.
    Rigacci, L.
    Stelitano, C.
    Zaja, F.
    Martelli, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 106 - 106
12345